Skip to main content

Table 3 Medications for COPD used by all PH-COPD patients and by RHC and PFT subgroups

From: Medication use by US patients with pulmonary hypertension associated with chronic obstructive pulmonary disease: a retrospective study of administrative data

Medication

All PH-COPDa (N = 25,975)

RHCa (N = 2325)

PFTa (N = 2995)

Any COPD medication

17,765 (100%)

1670 (100%)

2100 (100%)

Short-acting beta agonistb

13,083 (73.6%)

1203 (72.0%)

1472 (70.1%)

Short-acting anticholinergicb

5692 (32.0%)

478 (28.6%)

516 (24.6%)

Long-acting beta agonistb

6674 (37.6%)

634 (38.0%)

761 (36.2%)

Long-acting anticholinergicb

4756 (26.8%)

448 (26.8%)

388 (18.5%)

Inhaled corticosteroidb

14,906 (83.9%)

1393 (83.4%)

1788 (85.1%)

PDE4 inhibitor

367 (2.1%)

35 (2.1%)

19 (0.9%)

Fixed-dose combination

   

  Bronchodilator/ inhaled corticosteroid

7530 (42.4%)

743 (44.5%)

884 (42.1%)

  Bronchodilator/bronchodilator

2709 (15.2%)

290 (17.4%)

260 (12.4%)

  Triple therapyc

880 (5.0%)

82 (4.9%)

58 (2.8%)

  1. COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test; PH, pulmonary hypertension; RHC, right-heart catheterization
  2. aThe denominators for the percentages are the Ns with any COPD medication
  3. bMedication taken either alone or in a combination
  4. cFluticasone furoate/umeclidinium/vilanterol